Conference abstractPublished 8 Oct 2015
Novel and innovative strategies for peptide based drug design against Alzheimer’s disease
Indian Institute of Technology Guwahati, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Alzheimer’s Disease (AD), a common amyloidosis, has no cure yet. Pathological investigations revealed existence of numerousrnplaques in the Alzheimer’s patients’ brain composed of Amyloid-β (Aβ) peptides, derived from Amyloid Precursor Proteinsrn(APPs). Although the mechanism of plaque formation is unknown, AD is believed to be caused by the aggregation of misfoldedrnAβ peptides. β-breaker peptides have been developed that disrupt amyloid aggregates (plaques) in vitro as well as in vivo. We haverndeveloped two novel and innovative strategies for β-breaker peptide design. First one is based on the concept of β-sheet breaker α/βrnhybrid peptides (BSBHps); and the second one on the concept of β-Breaker Di-Peptides (BBDPs). We have demonstrated that suchrnwell designed peptides are capable of inhibition of amyloid formation of Aβ peptide. Also, they disrupt preformed toxic fibrillarrnaggregates into non toxic species in vitro. Such peptides may be useful for designing novel drugs against diverse amyloidoses includingrnAlzheimer’s disease, Parkinson’s disease and diabetes type II. Recent advancements in this direction of research will be discussed inrnthe Pharma Summit-2015.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectNeuroscience & Neurology
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Bhubaneswar Mandal”
